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Given the racial/ethnic disparities in breast cancer, we evaluated the association between
CYP19A1 single nucleotide polymorphisms (SNPs) on disease progression in women
with breast cancer from different racial/ethnic backgrounds. This is a cross-sectional
analysis of data from 327 women with breast cancer in the Expanded Breast Cancer
Registry program of the University of New Mexico. Stored DNA samples were analyzed
for CYP19A1 SNPs using a custom designed microarray panel. Genotype-phenotype
correlations were analyzed. Of the 384 SNPs, 2 were associated with clinically significant
outcomes, the rs4646 and rs12592697. The T allele for the rs4646 was associated
with advanced stage of the disease at the time of presentation (odds ratio [OR]:1.8,
confidence intervals [CI]: 1.05–3.13, p < 0.05) and a more progressive disease (OR: 2.1
[CI: 1.1–4.0], p = 0.04). For the rs12592697, the variant T allele was more frequent
in Hispanic women and associated with a more progressive disease (OR: 2.05 [CI:
1.0–4.0], p = 0.04). However, further analysis according to menopausal status showed
that the association between these 2 SNPs with disease progression or the stage at
diagnosis are confined only to postmenopausal women. The odds ratios of disease
progression among postmenopausal women carrying the T allele for the rs4646 and
rs12592697 are 3.05 (1.21, 7.74, p= 0.02) and 3.80 (1.24, 11.6, p= 0.02), respectively.
Regardless, differences in disease progression among the different genotypes for both
SNPs disappeared after adjustment for treatment. In summary, the rs4646 and the
rs12592697 SNPs in CYP19A1 are associated with differences in disease progression
in postmenopausal women. However, treatment appears to mitigate the differences in
genetic risk.
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INTRODUCTION
Breast cancer is the most common cancer diagnosed among
women in the US regardless of race or ethnicity; however,
disparities in both breast cancer incidence and mortality exist
between the various racial/ethnic groups (ACS Cancer Facts
& Figures, 2014). The reason for these disparities is likely
multifactorial. Data from epidemiological studies suggest that
socioeconomic status and educational level, as well as body
mass index, may contribute to the difference in prognosis
in different racial groups (Berz et al., 2009; Amadou et al.,
2014; Shariff-Marco et al., 2014). However, several reports
suggest that tumor biology, which accounts for the indolent or
aggressive nature of the disease, may explain the disparities in
the outcomes in these racial/ethnic groups (Carey et al., 2006;
Hines et al., 2011). For instance, results from a study showed
higher prevalence of estrogen receptor negative (ER-) tumors
and higher proportion of human epidermal growth factor
receptor 2 positive (HER2+) tumors in Hispanic women
(Hines et al., 2011), while others reported that African-
Americans (AA) are more likely to present with ER- than non-
Hispanic white (NHW) women (Chen et al., 1994; Chu et al.,
2001).
The CYP19A1 encodes for aromatase, the enzyme
responsible for the conversion of the adrenal androgen
androstenedione to estrone; the main source of estrogen
production in postmenopausal women (Forney et al., 1981).
Several polymorphisms of CYP19A1 were found to be associated
with differences in enzyme activity and circulating estradiol
levels in postmenopausal women and in elderly men (Gennari
et al., 2004; Somner et al., 2004; Riancho et al., 2009). It is
assumed that the alteration in hormone levels associated
with these polymorphisms is responsible for the observed
differences in the risk for breast cancer (Kristensen et al.,
2000; Talbott et al., 2008; Sergentanis and Economopoulos,
2010), bone loss and fractures (Masi et al., 2001; Gennari
et al., 2004; Somner et al., 2004), and response to aromatase
inhibitors (AI) in certain gene variants (Colomer et al.,
2008; Garcia-Casado et al., 2010). However, little is known
about the influence of genetic variations in CYP19A1 on the
differences in disease behavior among different racial/ethnic
groups. Since genetic polymorphisms in the CYP450 genes
vary according to race/ethnicity (Napoli et al., 2009), it is
possible that polymorphisms in CYP19A1 may, in part,
account for the racial/ethnic differences in the risk and
disease behavior of hormone-related diseases such as breast
cancer. For instance, it may impact disease progression and
response to endocrine therapy for breast cancer that could
ultimately translate into racial differences in disease outcomes.
The objectives of this study are to determine the prevalence
of CYP19A1 polymorphisms and their association with
disease progression among women from different racial/ethnic
backgrounds. We hypothesize that certain polymorphisms
in CYP19A1 are associated with racial/ethnic differences in
allele frequencies resulting in differences in the risk of disease
progression and stage at presentation among women with breast
cancer.
MATERIALS AND METHODS
Study Design
This is an analysis of the clinical data of the patients participating
in the Expanded Breast Cancer Registry (EBCR) program at
the University of New Mexico Comprehensive Cancer Center
(UNMCCC), Albuquerque, NM, USA and who had at least
1 follow-up since enrollment. The study was conducted in
accordance with the guidelines in the Declaration of Helsinki
for the ethical treatment of human subjects. The protocol was
approved by the University of New Mexico Institutional Review
Board. The study participants were recruited primarily from
the patients attending the UNMCCC Breast Clinic. A written
informed consent was obtained from each subject after a detailed
explanation of the nature of the study. The EBCR project
was initiated in the month of Februray 2006 and follow-up of
patients is ongoing. The primay objective is to estblish a registry
that will prospectively collect specified tissue samples along
with demographics, clinicopathologic variables and treatment
information on breast cancer patients seen at the UNMCCC.
The plans for the cohort is to augment the existing hospital
registry and assist researchers in identifying unique factors that
may impact outcomes of patients with breast cancer in New
Mexico. Stored DNA samples from patients enrolled in the EBCR
were analyzed for polymorphisms in CYP19A1, and stored serum
samples were assayed for serum estradiol.
Study Population
For this specific study, the population consists of the first 327
women participants of the EBCR program. These participants
were followed-up at the UNMCCC, Albuquerque, NM, USA
every 6 months for 1 to up to 6 years, from 2/16/2006 to
03/06/2012. Although, males were not specifically excluded, the
first 327 participants of the EBCR included in this study did not
include any males, likely because breast cancer is less common
among men. The specific inclusion and exclusion criteria for
the EBCR are described below. This study was not designed to
target a subgroup of participants considered as members of the
vulnerable population group.
Inclusion Criteria
All patients who are 18 years of age or older with pathological
diagnosis of breast cancer; regardless of gender, ethnicity/race,
stage of disease or treatment; must be less than or equal to 1 year
from the diagnosis of non-metastatic breast cancer, or less than or
equal to 1 year from initiation of treatment for metastatic disease;
must be available for clinical follow-up; and must be willing to
provide written, informed consent.
Exclusion Criteria
Patients who are younger than 18 years of age; without
pathological proof of diagnosis of breast cancer; unable to
provide clinical follow-up; unable to provide informed consent
in accordance with institutional and federal guidelines.
Data Collection
The clinical chart of these subjects were examined primarily for
disease progression, stage and treatment. A progressive disease
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is defined as transformation to a more advanced stage compared
to the stage at the time of presentation, recurrent disease or the
development of a new tumor. Other data collected include self-
reported race/ethnicity, estrogen receptor/progesterone receptor
(ER/PR) and HER2 status, age at diagnosis, menopausal status,
years since menopause, body mass index (BMI) which was
calculated as weight in kilograms/square of the height in meters,
and family history of breast cancer.
Biochemical Analysis
Baseline serum estrodiol assay was performed from stored serum
using ultrasensitive Elisa assay (Alpco Diagnostics, Salem, NH).
The assay sensitivity for estradiol using this kit was 1 pg/ml. The
coefficient of variablity of this assay in our lab is <10% (Aguirre
et al., 2015).
Genotyping
Genotyping was performed by oligonucleotide microarray
(BeadArray technology, Golden Gate [GG]; Illumina). DNA
probes—Custom genotyping panel was created for CYP19A1
using Illumina’s R© Golden Gate R© technology and Assay Design
Tool (ADT). SNP’s were selected within the CYP19A1 and
submitted to Illumina R© for probe design using Illumina’s R©
Assay Design Tool (ADT). QC metrics are returned and SNPs
were selected based on their likelihood for success within the
parameters of the assay and their potential to be functionally
active according to their location in the gene, or their previous
associations with differences in estradiol levels, gene expression,
transcriptional acitivity, and reported risk for breast cancer.
At the time of conception of this study,∼980 SNPs were listed
in the NCBI. We selected panel of 384 validated SNPs that met
the above criteria.
SNPs were removed from the analysis if they had call rates of
<94%, with minor allele frequency of <5% and deviated from
the Hardy-Weinberg equilibrium, leaving 119 SNPs available for
analysis in our current study. In this study, the main reason SNPs
were excluded was for low minor allele frequency. Regardless, we
paid particular attention to the SNPs reported to be associated
with breast cancer outcomes (Hadfield and Newman, 2012);
(rs4646, rs10046, rs700519, rs700518) (Colomer et al., 2008;
Garcia-Casado et al., 2010; Hadfield and Newman, 2012); and
SNPs associated with differences in circulating estradiol levels
(rs700518 and rs1062033, rs10046; Dunning et al., 2004; Riancho
et al., 2007, 2009), ezymatic activity (rs1062033) (Riancho et al.,
2009) and gene expression (rs10046) (Kristensen et al., 2000;
Colomer et al., 2008; Garcia-Casado et al., 2010; Hadfield and
Newman, 2012).
Statistical Analysis
Results were expressed as means ± SD. The primary outcome
in this study is disease progression, and disease stage at the
time of presentation or diagnosis is the secondary outcome. We
also analyzed other variables including estradiol levels, hormone
receptor and HER2 receptor status which may contribute to
disease (breast cancer) behavior. Group comparisons were done
by analysis of variance (ANOVA) for continuous variables and
by chi-square analysis for categorical variables. Odds ratios were
calculated using logistic regression analysis. Kaplan-Meier curves
were obtained by survival analysis. The data were managed using
Excel 2010 (Microsoft, Redmond, WA) and were analyzed using
SAS version 9.3 (SAS Institute, Inc., Cary, NC, USA).
RESULTS
Data from 327 women were analyzed. Table 1 shows the clinical
characteristics of the women. There were 325 women who
responded to their racial/ethnic background and 322 women
whose menopausal status can be verified or inferred. For the
TABLE 1 | Clinical characteristics of the entire study population.
Age (years) 53.2 ± 10.79
BMI (kg/m2) 28.6 ± 6.68
Menopausal status (N = 322)
Premenopausal 105 (32.6%)
Perimenopausal 27 (8.4%)
Postmenopausal 190 (59.0%)
History of postmenopausal hormone therapy 103/324 (31.8%)
Racial/Ethnic distribution (N = 325)
Non-Hispanic whites 164 (50.5%)
Hispanics 119 (36.6%)
African-Americans 11 (3.4%)
American Indians 18 (5.5%)
Asians 2 (0.6%)
Multiracial 11 (3.4%)
Baseline serum estradiol (pg/ml) 24.5 ± 28.4
Receptor status
ER
Positive 224/312 (71.8%)
Negative 88/312 (28.2%)
PR
Positive 180/308 (58.4%)
Negative 128/308 (41.6%)
HER2
Positive 64/287 (22.3%)
Negative 223/287 (77.7%)
Triple negative 59/315 (18.7%)
Stage at presentation (N = 324)
Stage 0–II 247 (76.2%)
Stage III–IV 77 (23.8%)
Progressive disease 57/312 (18.3%)
Baseline serum estradiol 24.5 ± 28.4
Formats of cell entries are mean ± SD or frequency/n (%). BMI, body mass index; ER,
Estrogen receptor, PR, progesterone receptor; HER2, Human epidermal growth factor
receptor 2.
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purpose of the study, women who did not respond to the
menopausal status questionnaire, were considered menopausal
if over the age of 50, while those who continued have periods
after age 50 were considered to be perimenopausal. As shown
in the table, majority of our subjects were NHW (50.5%) and
Hispanic (36.6%) women. As expected more women had HR+
disease and significantly less HER2+ tumors. Only 18.7% of
women had triple negative breast cancer (TNBC). Majority of the
women (76.2%) presented at early stages of the disease (stage 0–
II) while 23.8% presented at later stages of the disease (Stage III–
IV). Over the observation period of 6 years, 57 of the 312 patients
(18.3%) had progressive disease. Of the 312 women, 195 were on
antiestrogen therapy namely: 83 were on aromatase inhibitors, 95
were on selective estrogen receptor modulators (SERMs), while
17 were initially on either a SERM and switched to an AI or
vice-versa.
Table 2 shows the comparison beween NHW and Hispanic
women which constitute the majority of the racial groups
in our population. Hispanic women were much younger and
have higher BMI than the NHW. There were also significantly
more Hispanic women diagnosed with breast cancer during
the premenopausal stage compared to NHW, while significanlty
more NHW women had a history of postmenopausal hormone
replacement therapy (HRT). There was no difference in the
number of HR+ tumors in both NHW and Hispanic women.
However, there were signficantly more NHW women who were
HER2+. Hispanic women tend to have a higher proportion of
TNBC and more progressive disease but the differences were not
statistically signficant.
We found two SNPs that are associated with important clinical
outcomes, the rs4646 located at the 3′UTR and the rs12592697
located in the intronic sequence. Three hundred seven subjects
were successfully genotyped for the rs4646 polymorphism with
the following genotype frequency: CC = 145, CT = 128 and
TT = 34. As shown in Table 3, the minor T allele (the variant
allele) for this SNP was associated with a more advanced disease
stage at the time of diagnosis (odds ratio [OR]:1.8, confidence
intervals [CI]: 1.05–3.13, p < 0.05). In addition, the minor T
allele was also associated with a more progressive disease over the
observation period (OR: 2.1 [CI: 1.1−4.0], p = 0.04). However,
the difference in disease behavior between the genotypes was
lost when adjusted for treatment (p = 0.13) status. There was
no difference in the proportion of HR+ and HER2+ tumors
and TNBC between the genotypes. There was no significant
difference in genotype frequency for this polymorphism across
racial groups; in particular, there was no difference in frequency
between the NHW (CC = 77/154, CT = 63/154, TT = 14/154
and Hispanic women (CC = 50/112, CT = 47/112, TT =
15/112).
Another SNP found to be associated with a difference in
clinical outcome was the rs12592697 (Table 4). Three hundred
six subjects were successfully genotyped for this polymorphism;
the genotype frequency was CC = 111, CT = 151, and TT =
44. There were proportionately greater number of women with
the minor T allele who were premenopausal compared to those
without the T allele. Among the 293 patients with known ER
status, significantly more patients classified as ER- were carriers
of the T allele. There was a trend for women with PR- tumors to
be carriers of the T allele. In addition, among patients with data
on disease progression, a greater proportion of subjects carrying
the T allele (22%) had a progressive disease compared to 12.0%
of patients without the T allele (OR: 2.05 [CI 1.0–4.0), p = 0.04].
Further analysis showed that ER positivity or PR positivity are
related to progression for this SNP (both P < 0.001). However,
the combined ER positivity and PR positivity is not related to
progression among variants of rs12596297 (P = 0.75). Again,
the difference in disease behavior disappeared after adjusting
for treatment status (p = 0.26). Among NHW (n = 154), the
genotype frequency was: CC = 64, CT = 70, and TT = 20,
while in Hispanics (n = 111) it was: CC = 32, CT = 60, and
TT= 19.
Although there was no difference in genotype frequency
among the different races, a separate comparison between NHW
and Hispanics for the rs12596297 showed that the T allele was
TABLE 2 | Comparison between non-Hispanic and Hispanic women
participants.
Non-Hispanic white Hispanic P-values
(n = 164) (n = 119)
Age 55.5 ± 10.1 50.7 ± 10.9 0.001
BMI 27.4 ± 6.6 29.9 ± 6.3 0.002
Menopausal status (N = 149) (N = 101) 0.01
Premenopausal 34 (22.82%) 41 (40.6%)
Perimenopausal 9 (6.04%) 4 (4.0%)
Menopausal 106 (71.14%) 56 (54.4%)
History of postmenopausal
hormone therapy
70/163 (42.9%) 18/118 (15.3%) <0.001
Receptor status
ER (N = 157) (N = 114) 0.96
Positive 112/157 (71.3%) 81/114 (71%)
Negative 45/157 (28.7%) 33/114 (29%)
PR (N = 158) (N = 108) 0.67
Positive 88/158 (55.7%) 63/108 (58.3%)
Negative 70/158 (44.3%) 45/108 (41.7%)
HER2 (N = 145) (N = 104) <0.05
Positive 39/145 (26.9%) 17/104 (16.4%)
Negative 106/145 (73.1%) 87/104 (83.6%)
Triple negative 26/158 (16.5%) 26/115 (22.6%) 0.20
Progressive disease 24/157 (15.3%) 25/113 (22.1%) 0.15
Stage at diagnosis 0.65
Stage 0–II 125/163 (76.7%) 87/117 (74.4%)
III–IV 38/163 (23.3%) 30/117 (25.6%)
Baseline serum estradiol 25.1 ± 23.5 27.6 ± 36.4 0.66
Formats of cell entries are mean ± SD or frequency/n (%). BMI, body mass index; ER,
Estrogen receptor; PR, progesterone receptor; HER2, Human epidermal growth factor
receptor 2. Bold values indicate that the p-value is statistically significant.
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TABLE 3 | Clinical features and tumor characteristics of patients according to the rs4646 polymorphism.
CC (N = 145) CT/TT (N = 162) P
Age 53.7 ± 10.5 52.5 ± 11.0 0.33
BMI 28.5 ± 6.8 29.0 ± 6.8 0.52
Menopausal status (N = 144) (N = 159) 0.89
Premenopausal 47 (32.6%) 55 (35.6%)
Perimenopausal 9 (6.3%) 11 (6.9%)
Postmenopausal 88 (61.1%) 93 (58.5%)
History of postmenopausal hormone
therapy
47/142 (33.1%) 49/162 (30.2%) 0.59
Racial/Ethnic distribution
Non-Hispanic whites (N = 154) 77/154 (50.0%) 77/154 (50.0%) 0.62
Hispanic whites (n = 112) 50/112 (44.6%) 62/112 (55.4%)
*Others (N = 41) 18/41 (43.9%) 23/41 (56.1%)
Receptor Status
ER (N = 141) (N = 153) 0.96
Positive 101/141 (71.6%) 110/153 (71.9%)
Negative 40/141 (28.4%) 43/153 (28.1%)
PR (N = 137) (N = 153) 0.37
Positive 85/137 (62.0%) 87/153 (56.9%)
Negative 52/137 (38.0%) 66/153 (43.1%)
HER2 (N = 130) (N = 142) 0.62
Positive 27/130 (20.8%) 33/142 (23.2%)
Negative 103/130 (79.2%) 109/142 ((76.8%)
Triple negative 26/141 (18.4%) 30/156 (19.2%) 0.86
Progressive disease 17/137 (12.4%) 36/155 (23.2%) 0.02
Stage at diagnosis
Stage 0–II 118/144 (81.9%) 113/160 (70.6%) 0.02
III–IV 26/144 (18.1%) 47/160 (29.4%)
Estradiol (pg/ml) 24.1 ± 32.1 26.0 ± 24.4 0.71
Formats of cell entries are mean± SD or frequency/n (%). BMI, body mass index; *African-Americans, Native Americans, Asians, and multiracial. ER, Estrogen receptor; PR, progesterone
receptor; HER2, Human epidermal growth factor receptor 2. Bold values indicate that the p-value is statistically significant.
significantly more prevalent in Hispanic (71.2%) compared to
NHW (59.6 %) women (p= 0.03).
Since less than 10% of our entire study population consisted
of perimenopausal women, we focused our analysis primarily
the premenopausal and postmenopausal women. Dividing the
appropriate subjects into these two groups showed that the
association between the SNPs and outcomes are confined
to postmenopausal women only (Tables 5, 6). There were
no differences in any outcome measure for rs4646 and
rs12592697 among premenopuasal women. By contrast, there
were significantly more postmenopausal women carrying the
T allele for the rs4646 who have progressive disease and a
more advanced stage at the time of diagnosis. For rs12592697,
significantly more postmenopausal women carrying the T allele
are ER- and have a more progressive disease. In addition, there
were trends for carriers of the T allele to have HR- tumors
(i.e., less of either ER+, PR+ or both ER+/PR+) compared
to those homozygous for the C allele among postmenopausal
women. Again, adjustment for treatment status eliminated
the differences in disease progression among the genotypes
for both SNPs (p = 0.13 for rs4646 and p = 0.28 for
rs12592697).
Time to progression using Kaplan-Meier analyses among
postmenopausal women showed a trend for a lower disease
progression-free probabality among women carrying the T allele
for both SNPs, Figure 1 (Figure 1A for rs4646 and Figure 1B
for rs12592697). The odds ratios of disease progression among
postmenopausal women carrying the T allele for the rs4646 and
rs12592697 are 3.05 (1.21, 7.74, p = 0.02) and 3.80 (1.24, 11.6,
p = 0.02), respectively. For untreated postmenopausal women,
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TABLE 4 | Clinical features and tumor characteristics of patients according to the rs12592697 polymorphism.
CC (N = 111) CT/TT (N = 195) P
Age 53.2 ± 10.4 53.0 ± 11.1 0.90
BMI 28.2 ± 6.9 29.0 ± 6.7 0.36
Menopausal status (n = 302)
Premenopausal 31 (28.4%) 70 (36.3%) 0.04
Perimenopausal 12 (11.0%) 8 (4.1%)
Postmenopausal 66 (60.6%) 115 (59.6%)
History of postmenopausal hormone therapy 35/108 (32.4%) 62/197 (31.5%) 0.87
Racial/Ethnic distribution
Non-Hispanic whites (N = 154) 64/154 (41.6%) 90/154 (59.6%) 0.10
Hispanic whites (N = 111) 32/111 (28.8%) 79/111 (71.2%) **NHW vs. Hispanics only P = 0.03
*Others (N = 41) 15/41 (36.6%) 26/41 (63.4%)
Receptor status
ER (N = 108) (N = 185) 0.04
Positive 85/108 (78.7%) 125/185 (67.6%)
Negative 23/108 (21.3%) 60/185 (32.4%)
PR (N = 137) (N = 182) 0.08
Positive 71/137 (66.4%) 100/182 (54.9%)
Negative 36/137 (33.6%) 82/182 (45.1%)
HER2 (N = 94) (N = 177) 0.50
Positive 23/94 (24.5%) 37/177 (20.9%)
Negative 71/94 (75.5%) 140/177 (79.1%)
Triple negative 19/107 (17.8%) 38/191 (19.9%) 0.65
Progressive disease 13/108 (12.0%) 40/182 (22.0%) 0.03
Stage at diagnosis (n = 303) 0.49
Stage 0–II 86/110 (78.2%) 144/193 (74.6%)
III–IV 24/110 (21.8%) 49/193 (25.4%)
Estradiol (pg/ml) 26.8 ± 37.3 24.3 ± 22.5 0.65
Formats of cell entries are mean± SD or frequency/n (%), BMI, body mass index; *African-Americans, Native Americans, Asians, and multiracial. ER, Estrogen receptor; PR, progesterone
receptor; HER2, Human epidermal growth factor receptor 2; **Comparison of allele/genotype frequency between NHW and Hispanics only by T-test. Bold values indicate that the p-value
is statistically significant.
the odds ratios of disease progression for carriers of the T allele
of the rs4646 and rs12592697 are 7.49 (1.90, 29.5, p = 0.004)
and 3.01 (0.77, 11.7, p = 0.11), respectively. Analysis of women
on AI alone (n = 83) show odds ratios for disease progression
for carriers of the T allele for the rs4646 and rs12592697 to
be 1.22 (0.36, 4.18 p = 0.75) and 3.18 (0.65, 15.7 p = 0.15),
respectively.
The genotype frequencies for both rs4646 and rs12592697
were in Hardy-Weinberg equilibrium in our population (http://
www.had2know.com/academics/hardy-weinberg-equilibrium-
calculator-2-alleles.html).
DISCUSSION
Our results demonstrated that rs4646 polymophism of CYP19A1
was associated with differences in the disease progression and
stage at the time of diagnosis. The T allele was associated
with a more advanced stage of the disease at the time of
presentation and a more progressive disease. We did not find
any ethnic differences in genotype frequencies for the rs4646
polymorphism. However, the rs12592697 polymorphism, was
associated with ethnic differences in genotype frequency;
there were significantly higher proportion of Hispanic white
women who were carriers of the minor T allele relative to
NHW women. In addition, more women with progressive
disease were carriers of the T allele. A separate analysis between
premenopausal and postmenopausal women showed that
the associations between the 2 SNPs and disease progression
were only observed in postmenopausal women. Similarly, the
association between rs4646 and the disease stage at the time
of diagnosis was only observed in postmenopausal women.
However, it appeared that the influence of both polymorphism
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TABLE 5 | Analysis of the different clinical characteristics and outcomes
according to rs4646 and rs12592697 polymorphisms in the CYP19A1 in
premenopausal women with breast cancer.
rs4646 CC (N = 85) CT/TT (N = 86)
ER
Positive 27/44 (61.4%) 34/53 (64.2%) 0.78
Negative 17/44 (38.6%) 19/53 (35.8%)
PR
Positive 25/44 (56.8%) 30/53 (56.6%) 0.98
Negative 19/44 (43.2%) 23/53 (43.4%)
ER+/PR+ 25/43 (58.1%) 30/51 (58.8%) 0.96
HER2+ 9/41 (21.9%) 11/50 (22%) 0.99
Triple negative 12/44 (27.3%) 17/53 (32.1%) 0.61
Progressive disease 9/44 (20.5%) 15/53 (28.3%) 0.37
Stage at diagnosis
Stage 0–II 35/46 (76.1%) 36/55 (65.5%) 0.24
III–IV 11/46 (23.9%) 19/55 (34.5%)
Estradiol (pg/ml) 36.2 ± 26.2 37.8 ± 44.2 0.89
rs12592697 CC CC/TT
ER
Positive 22/31 (71.0%) 39/66 (59.1%) 0.26
Negative 9/31 (29.0%) 27/66 (40.9%)
PR
Positive 19/30 (63.3%) 36/67 (53.4%) 0.38
Negative 11 (36.7%) 31/67 (46.3%)
ER+/PR+ 19/30 (63.3%) 36/65 (55.4%) 0.47
HER2+ 5/26 (19.2%) 15/65 (23.1%) 0.69
Triple negative 9/31 (29.0%) 20/66 (30.3%) 0.90
Progressive disease 8/31 (25.8%) 16/66 (24.2%) 0.87
Stage at diagnosis (n = 303)
Stage 0–II 20/30 (66.7%) 51/70 (72.9%) 0.40
III–IV 11/31 (35.5%) 19/70 (27.1%)
Estradiol (pg/ml) 47.2 ± 61.1 33.6 ± 24.4 0.30
Formats of cell entries are mean ± SD or frequency/n (%), ER+, Estrogen receptor
positive; PR+, progesterone receptor positive; HER2, Human epidermal growth factor
receptor 2.
on disease progression was attenuated by treatment
status.
In postmenopausal women, most of the circulating estrogen
comes from the conversion of adrenal androgens to estrone
by the enzyme aromatase, which is in turn interconverted to
estradiol. Several polymorphisms in the aromatase or CYP19A1
have been reported to be associated with hormone-related
disease such as osteoporosis and breast cancer (Masi et al.,
2001; Somner et al., 2004; Talbott et al., 2008; Sergentanis
and Economopoulos, 2010). The rs4646 polymorphism (C to
TABLE 6 | Analysis of the different clinical characteristics and outcomes
according to rs4646 and rs12592697 polymorphisms in the CYP19A1 in
postmenopausal women with breast cancer.
rs4646 CC CT/TT
N = 85 (49.7%) N = 86 (50.3%)
ER
Positive 68/87 (71.2%) 64/87 (73.6%) 0.48
Negative 19/87 (21.8%) 23/87 (26.4%)
PR
Positive 54/82 (65.9%) 48/86 (55.8%) 0.18
Negative 28/82 (34.1%) 38/86 (44.2%)
ER+/PR+ 53/82 (64.6%) 48/84 (57.1%) 0.32
HER2 17/80 (21.3%) 19/79 (24.1%) 0.67
Triple negative 11/85 (12.9%) 13/87 (14.9%) 0.71
Progressive disease 7/81 (8.6%) 20/88 (22.7%) 0.01
Stage at diagnosis
Stage 0–II 72/86 (83.7%) 65/91 (71.4%) 0.05
III–IV 14/86 (16.3%) 26/91 (28.6%)
Estradiol pg/ml 13.6 ± 13.0 15.8 ± 16.1 0.54
rs12592697 CC CC/TT
ER
Positive 52/62 (83.9%) 80/113 (70.8%) 0.05
Negative 10/62 (16.1%) 33/113 (29.2%)
PR
Positive 42/61 (68.9%) 60/108 (55.6%) 0.09
Negative 19/61 (31.1%) 48/108 (44.4%)
ER+/PR+ 42/60 (70.0%) 59/107 (55.1%) 0.06
HER2 15/55 (27.3%) 21/105 (20.0%) 0.30
Triple negative 7/60 (11.7%) 18/113 (15.9%) 0.45
Progressive disease 4/62 (6.5%) 23/108 (21.3%) 0.01
Stage at diagnosis (n = 303)
Stage 0–II 52/63 (82.5%) 86/115 (74.8%) 0.24
III–IV 11/63 (17.5%) 29/115 (25.2%)
Estradiol pg/ml 14.4 ± 14.5 14.6 ± 14.6 0.95
Formats of cell entries are mean ± SD or frequency/n (%), ER+, Estrogen receptor
positive; PR+, progesterone receptor positive; HER2, Human epidermal growth factor
receptor 2. Bold values indicate that the p-value is statistically significant.
T) at the 3′UTR has been reported to be associated with
differences in disease-free survival. For instance, the variant T
allele was found to be part of a haplotype that is associated
with poor disease-free survival in Taiwanese women (Kuo et al.,
2013). Furthermore, in a treatment study, the same allele was
associated with a lower progression-free survival compared to
those homozygous for the wild type (C) allele treated with
letrozole given as a neoadjuvant treatment in postmenopausal
women of Spanish ancestry with stage II–III ER/PR (+) breast
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FIGURE 1 | Kaplan-Meier distribution for disease progression-free probability among the genotypes for the rs4646 (A) and rs12592697 (B)
polymorphisms in the CYP19A1. Circles represent time of data censor.
cancer (Garcia-Casado et al., 2010). By contrast, in a study
among Chinese women with metastatic breast cancer, patients
with the variant allele had statistically significantly longer overall
survival compared to women homozygous for the wild type (37.3
vs. 31.6 mos, p = 0.007; Liu et al., 2013). Likewise, another
study in postmenopausal women with advanced breast cancer
of Spanish ancestry showed a significant improvement in time
to progression among those with the variant T allele (17.2
vs. 6.4 mos; p = 0.02) treated with letrozole (Colomer et al.,
2008). Our study showed that patients with the T allele for
the rs4646 presented with a more advanced disease than those
without the T allelemostly in postmenopausal women.Moreover,
these patients also had a more progressive disease. Although,
these results seem inconsistent, these studies were conducted
in different populations, with different ethnic backgrounds and
living in different geographical locations with different dietary
and lifestyle habits, all of which may interact with genetics to
influence phenotypes.
Polymorphisms in CYP19A1 vary across racial and ethnic
backgrounds (Janicki et al., 2013), and may explain the
different susceptibility, disease behavior and response to therapy
among hormone-related disorders across racial/ethnic groups.
In this study we did not find a racial/ethnic difference in
genotype frequency for the rs4646 polymorphism. However, the
rs12592697 in the intronic region of CYP19A1 was associated
with differences in genotype frequency between NHW and
Hispanic women. To our knowledge, there has been no clinical
association reported for this SNP except that it is in linkage
with a SNP that maybe associated with significant differences
in estradiol levels among the variants (Prescott et al., 2012).
In our study, the variant T allele which is more prevalent in
Hispanic women, was associated with a higher proportion of
ER- tumors and a more progressive course of breast cancer
in postmenopausal women. Nonetheless, it remains unknown
whether this allele contributes to poorer outcomes of breast
cancer among Hispanics relative to NHW women in general.
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A variant allele for another polymorphism, the rs10046,
has been reported to be associated with higher estradiol levels
(Dunning et al., 2004) and higher frequency in women with
breast cancer (Kristensen et al., 2000). In our study there was
no significant increase in estrogen levels in the variants for both
rs4646 and rs12592697 at baseline regardless of menopausal
status. However, this finding is not unusual as other studies
also failed to show differencess in levels of circulating estrogen
in other clinically important CYP19A1 SNPs (Napoli et al.,
2013). Of importance in breast cancer, are data by some
investigators of an increase in local aromatase activity in breast
tissues in certain variants which may influence hormone levels
on the tumor microenvironment and in turn correlate with
disease behavior (Kristensen et al., 2000). In addition, prior
investigators have reported a higher risk for breast cancer
among women with higher levels of androgens independent of
estrogen levels (Missmer et al., 2004; Peters et al., 2009) and
although androgen receptor positivity is associated with better
prognosis in ER+ breast cancers (Peters et al., 2009), it is also
associated with acquired resistance to anti-estrogen (De Amicis
et al., 2010; Rechoum et al., 2014). Whether androgen levels
and androgen receptor activity have roles as mediators in the
observed association between the SNPs and outcomes have not
been explored in our study.
Aside from being considered as a risk factor for breast
cancer, a high body weight is also associated with higher risk
for recurrence and reduced survival (Jain et al., 2013; Azrad
and Demark-Wahnefried, 2014). In addition, there are studies
suggesting that AIs may not be as effective in obese women
with HR+ breast cancer as compared to women with normal
weight (Pfeiler et al., 2013). Since the prevalence of obesity is
higher in certain racial/ethnic groups (An, 2014), it is possible
that this may contribute to poor breast cancer outcomes in
certain racial/ethnic groups compared to others. In addition, age
is an important determinant of prognosis. Younger women who
tend to be premenopausal with a higher rate of triple negative
tumors at the time of breast cancer diagnosis are likely to have
poorer outcomes than older women (Ray and Polite, 2010). In
our study, regardless of the findings that Hispanic women had
higher BMI, were significantly younger with a greater proportion
of them being premenopausal, we cound not find a difference
in the risk for a progressive disease between the Hispanic and
NHW women in the population as a whole. On the other hand,
HER2 positivity which is associated with poorer prognosis is
much higher in NHW than Hispanic women and may have
modified the effects of age, menopausal status and BMI on
disease behavior between the races. However, our sample size
is quite limited to make a definitive conclusion. There was no
difference in BMI, age and receptor status among genotypes
for the rs4646 to account for the difference in disease stage at
the time of presentation nor disease progression. Meanwhile, a
significant number of women with the T allele for the rs12592697
are premenopausal and are also ER negative. It is possible that
these features may have contributed to amore progressive disease
among patients with the T allele for this polymorphism.However,
analysis by menopausal status showed that the association
between these SNPs and our outcomes are only obeserved
in postmenopausal women and the association between the 2
SNPs and disease behavior does not exist in premenopausal
women. This finding underscores the important role of the
aromatase enzyme activity as determinant of hormonal status
after cessation of ovarian function. Our findings also suggest that
ER positivity or PR positivity may contribute to the association
between CYP19A1 SNPs and outcomes in postmenopausal
women, in particular rs12592697, perhaps suggesting an
interaction between hormone receptor signaling in some of these
SNPs.
Our results showed that the association between the 2 SNPs
disappeared with adjustment for treatment. We also found that
the T allele in both SNPs was associated with overall higher odds
of disease progression mostly in the untreated group, while a
separate analysis of women on AIs alone revealed no significant
differences in disease progression associated with both SNPs. It is
likely that the amount of estrogen present in the postmenopausal
period, albeit small, is still able to produce significant difference
in biological effects on the breast among women belonging to
the different genotypes in the absence of treatment; and this
difference is eliminated by antiestrogens resulting in comparable
disease progression. On the other hand, it is also conceivable
that the limited sample size prevented us from detecting a
difference in response, more specifically in the small number of
women who are on AI. In addition, as these data are obtained
from chart review, the actual compliance (which could affect
disease behavior) among these patients on the prescribed therapy
remains unknown.
Our study has limitations. Being cross-sectional in design, the
data presented here is limited to what is avilable in the patient’s
medical record. In addition, race/ethnicity was categorized based
on self-reporting by the patient (i.e., not verified for instance
by ancestry informed markers), and all recruited in the same
institution both of which may introduce bias. We also did not
correct for multiple comparisons in our study. Furthermore, the
relativley short period of follow-up limits our ability to assess the
more important outcome which is mortality. Functionality of the
SNPs studied is likewise not addressed in this study. Although,
the underlying mechanism by which these SNPs influence
disease behavior or even response to AI treatment is unclear,
it is conceivable that our findings could result in hypothesis
generating projects to further elucidate the mechanism for our
observations. For instance, it is possible that variant alleles result
in enhanced gene expression; or posttranslational modification
with change in protein structure resulting in a more active
enzyme, or that they could be in linkage with functionally active
SNPs resulting in higher estrogenic environment.
CONCLUSIONS
Two SNPs in CYP19A1 were associated with disease outcomes
particularly in the cohort of postmenopausal women diagnosed
with breast cancer at our institution. Postmenopausal women
with the T allele for the rs4646 polymorphism located at the
3′UTR had a more advanced disease at the time of presentation
and a more progressive disease than those without the T allele.
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Another SNP, rs12592697, in the intronic region of CYP19A1
was associated with differences in allele frequency between
NHW and Hispanic women with breast cancer. The variant T
allele was found to be more frequent in Hispanic than NHW
women. Furthermore, this allele was associated with a more
progressive disease in postmenopausal women relative to the wild
type. Despite the genetic predisposition for a more advanced
and progressive disease among certain variants for these 2
polymomorphisms, our results suggest that this association is
modified by treatment. Specifically, in our patient population,
anti-estrogen therapy prevented disease progression among
postmenopausal women with risk alleles for CYP19A1. If proven
to be true, our findings may have significant clinical implications
for patients carrying these risk alleles. For instance, in patients
harboring the common genetic variations in CYP19A1, this
information may motivate them to become adherent to their
prescribed adjuvant endocrine therapy. It is well documented
that in women who start adjuvant endocrine therapy, rates
of non-persistence (early discontinuation of medication) range
from 20% to 50% and rates of non-compliance (nonconformity to
prescribed dosing) range between 16 and 26%, and worsen over
time (Hershman et al., 2010). These individualized information
may be a useful reminder that could encourage at risk patients to
continue with their recommended treatment. This is especially
important in light of the updated recommendations for longer
adjuvant endocrine therapy in HR+ disease (Burstein et al.,
2016) and potential for dramatic increased non-adherence rates
to adjuvant endocrine therapy.
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